Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product candidates from discovery to the clinic with improved success and lower cost.
Hereto, the company has developed a portfolio of technologies aimed to improve product yield (STEP®), reduce process development time (SIDUS®, SCOUT®) and increase product stability. These technologies have amply demonstrated to improve speed and reduce cost in biopharmaceutical development, accelerating the journey from bench to clinic.
The company employs a highly educated staff with many years of experience in DNA cloning, mammalian cell line generation, upstream process development (mammalian, microbial & insect cell platforms), purification development, product characterization, and clinical manufacturing. As such the company, with laboratories in USA and the Netherlands, is well positioned to take on any challenge associated with the development of complex biological medicines be it proteins, antibodies, vaccines or viral vectors.
Batavia Biosciences aims to significantly contribute to ease human suffering from disease by improving the success rate in the translation of candidate biopharmaceutical medicines from discovery to the clinic.
Batavia Biosciences actively develops know-how and technologies to support global health initiatives and the biopharmaceutical industry to bring new and improved medicines to the market.